Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer-Reference-Cited by-同舟云学术

Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer

Published:2005-10 Issue: Volume:59 Page:S323-S324
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Ohnoa S.,Toi M.,Kuroi K.,Nakamura S.,Iwata H.,Kusama M.,Masuda N.,Yamazaki K.,Hisamatsu K.,Sato Y.,Takatsuka Y.,Shin E.,Kaise H.,Kurozumi M.,Tsuda H.,Akiyama F.

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506);Breast Cancer Research and Treatment;2023-06-26

2. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter; NCT02001506);2022-09-08

3. Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study;Clinical Breast Cancer;2021-06

4. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial;The Lancet Oncology;2017-07

5. Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study;Medical Oncology;2015-10-31